Apr 27, 2017
Alkaloid marked 10% growth in consolidated sales, 11% growth in consolidated net profit, sales in Great Britain in amount of mkd 67.4 million and 30 new employments in the period January - March 2017
Alkaloid marked 10% growth in consolidated sales, 11% growth in consolidated net profit, sales in Great Britain in amount of mkd 67.4 million and 30 new employments in the period January - March 2017
Alkaloid AD Skopje achieved positive financial results in the period January-March 2017 - shows the unaudited standalone and unaudited consolidated Income Statement.
According to the unaudited standalone Income Statement, in the period January- March the sales reached the amount of MKD 1,781,320,547 - 11% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 342,090,242 marked an increase of roughly 12%, whereas the net profit amounting to MKD 203,498,490 rose by 9%.
In the period January – March the total consolidated sales reached MKD 2,332,909,055 – an increase of 10% compared to the same period last year. Consolidated sales in the domestic market increased by 11%, while the total consolidated export of the company increased by 9%.
Out of the total consolidated sales, 38% were realized in the domestic market, while the foreign markets account for 62%. The breakdown by region shows that the countries of South-East Europe account for 30% of the sales, Russia and CIS – 8%, 23% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 1% of the total consolidated sales. The highest rise in export markets was seen in the following countries: Great Britain reaching sales of MKD 67,462,665 – an increase of 4,275%, Russia – 36%, Romania – 63%, Slovenia - 28%, Croatia – 5%, Hungary- 369%, Czech Republic - 467%, Albania – 11% etc.
The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals – 85%, with OTC products accounting for 20%, cardiovascular products - 17%, neurological products – 13%, antibiotics - 15% etc. The Chemistry Cosmetics Botanicals segment accounts for 15% of the total consolidated sales, or more precisely Chemistry – 4%, Cosmetics – 8% and Botanicals – 3%.
Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 389,086,951 saw an increase of 12%, whereas the net consolidated profit amounting to MKD 231,180,196 went up by 11%.
The total investments in non-current assets for the period January – March 2017 amounted to MKD 128,227,342.
In the period January – March 2017 Alkaloid recruited 30 new employees in the Republic of Macedonia.